FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246041230> ?p ?o ?g. }

• W4246041230 abstract "<sec> <title>BACKGROUND</title> Increased incidence and life expectancy have resulted in a growing population of patients with metastatic breast cancer, and these patients experience high rates of morbidity and premature mortality. Increased physical activity (PA) is consistently associated with improved health and disease outcomes among early-stage survivors. However, there is a paucity of research on PA in patients with metastatic breast cancer, and existing PA interventions have exhibited low feasibility because of their focus on intense PA and/or requirement of on-site visits. Mobile health (mHealth)–based PA interventions may be particularly useful for patients with metastatic breast cancer because they allow for remote monitoring, which facilitates individual tailoring of PA recommendations to patients’ abilities and may minimize participant burden. However, no studies have examined mHealth PA interventions in patients with metastatic breast cancer. </sec> <sec> <title>OBJECTIVE</title> We aim to address these critical research gaps by testing a highly tailored technology-based intervention to promote PA of any intensity (ie, light, moderate, or vigorous) by increasing daily steps in patients with metastatic breast cancer. The primary aim of this study is to test the feasibility and acceptability of the Fit2ThriveMB intervention. We will also examine outcome patterns suggesting the efficacy of Fit2ThriveMB on symptom burden, quality of life, and functional performance. </sec> <sec> <title>METHODS</title> The Fit2ThriveMB trial is a two-arm pilot randomized controlled trial that will compare the effects of a smartphone-delivered, home-based PA intervention and an attention-control education condition on PA and quality of life in low-active female patients with metastatic breast cancer. A subsample (n=25) will also complete functional performance measures. This innovative trial will recruit 50 participants who will be randomized into the study’s intervention or control arm. The intervention will last 12 weeks. The Fit2ThriveMB intervention consists of a Fitbit, coaching calls, and the Fit2ThriveMB smartphone app that provides self-monitoring, a tailored goal-setting tool, real-time tailored feedback, app notifications, and a group message board. Assessments will occur at baseline and post intervention. </sec> <sec> <title>RESULTS</title> The Fit2ThriveMB study is ongoing. Data collection ended in February 2021. </sec> <sec> <title>CONCLUSIONS</title> Data from this study will provide the preliminary effect sizes needed to assemble an intervention that is to be evaluated in a fully powered trial. In addition, these data will provide essential evidence to support the feasibility and acceptability of using a technology-based PA promotion intervention, a scalable strategy that could be easily integrated into care, among patients with metastatic breast cancer. </sec> <sec> <title>CLINICALTRIAL</title> ClinicalTrials.gov NCT04129346; https://clinicaltrials.gov/ct2/show/NCT04129346 </sec> <sec> <title>INTERNATIONAL REGISTERED REPORT</title> DERR1-10.2196/24254 </sec>" @default.
• W4246041230 created "2022-05-12" @default.
• W4246041230 creator A5008305135 @default.
• W4246041230 creator A5020024040 @default.
• W4246041230 creator A5022131450 @default.
• W4246041230 creator A5033100685 @default.
• W4246041230 creator A5034458501 @default.
• W4246041230 creator A5046208523 @default.
• W4246041230 creator A5080987262 @default.
• W4246041230 creator A5081839961 @default.
• W4246041230 creator A5084639804 @default.
• W4246041230 creator A5085028425 @default.
• W4246041230 creator A5089229495 @default.
• W4246041230 creator A5089501244 @default.
• W4246041230 creator A5090867068 @default.
• W4246041230 date "2020-09-10" @default.
• W4246041230 modified "2023-09-26" @default.
• W4246041230 title "A Technology-Based Physical Activity Intervention for Patients With Metastatic Breast Cancer (Fit2ThriveMB): Protocol for a Randomized Controlled Trial (Preprint)" @default.
• W4246041230 cites W1587923037 @default.
• W4246041230 cites W1857624176 @default.
• W4246041230 cites W1965117448 @default.
• W4246041230 cites W1970675431 @default.
• W4246041230 cites W1982562953 @default.
• W4246041230 cites W1986169687 @default.
• W4246041230 cites W2004165060 @default.
• W4246041230 cites W2006331513 @default.
• W4246041230 cites W2010163891 @default.
• W4246041230 cites W2033657300 @default.
• W4246041230 cites W2043517828 @default.
• W4246041230 cites W2063323404 @default.
• W4246041230 cites W2070225606 @default.
• W4246041230 cites W2071698127 @default.
• W4246041230 cites W2074076764 @default.
• W4246041230 cites W2075063902 @default.
• W4246041230 cites W2096657471 @default.
• W4246041230 cites W2098094536 @default.
• W4246041230 cites W2101046684 @default.
• W4246041230 cites W2107748660 @default.
• W4246041230 cites W2116690431 @default.
• W4246041230 cites W2118491115 @default.
• W4246041230 cites W2136405350 @default.
• W4246041230 cites W2138831913 @default.
• W4246041230 cites W2139249918 @default.
• W4246041230 cites W2139994949 @default.
• W4246041230 cites W2141337908 @default.
• W4246041230 cites W2148367829 @default.
• W4246041230 cites W2153132692 @default.
• W4246041230 cites W2162812015 @default.
• W4246041230 cites W2169438989 @default.
• W4246041230 cites W2170398533 @default.
• W4246041230 cites W2254075657 @default.
• W4246041230 cites W2606327305 @default.
• W4246041230 cites W2616354594 @default.
• W4246041230 cites W2767880786 @default.
• W4246041230 cites W2795373908 @default.
• W4246041230 doi "https://doi.org/10.2196/preprints.24254" @default.
• W4246041230 hasPublicationYear "2020" @default.
• W4246041230 type Work @default.
• W4246041230 citedByCount "0" @default.
• W4246041230 crossrefType "posted-content" @default.
• W4246041230 hasAuthorship W4246041230A5008305135 @default.
• W4246041230 hasAuthorship W4246041230A5020024040 @default.
• W4246041230 hasAuthorship W4246041230A5022131450 @default.
• W4246041230 hasAuthorship W4246041230A5033100685 @default.
• W4246041230 hasAuthorship W4246041230A5034458501 @default.
• W4246041230 hasAuthorship W4246041230A5046208523 @default.
• W4246041230 hasAuthorship W4246041230A5080987262 @default.
• W4246041230 hasAuthorship W4246041230A5081839961 @default.
• W4246041230 hasAuthorship W4246041230A5084639804 @default.
• W4246041230 hasAuthorship W4246041230A5085028425 @default.
• W4246041230 hasAuthorship W4246041230A5089229495 @default.
• W4246041230 hasAuthorship W4246041230A5089501244 @default.
• W4246041230 hasAuthorship W4246041230A5090867068 @default.
• W4246041230 hasBestOaLocation W42460412302 @default.
• W4246041230 hasConcept C121608353 @default.
• W4246041230 hasConcept C126322002 @default.
• W4246041230 hasConcept C133925201 @default.
• W4246041230 hasConcept C159110408 @default.
• W4246041230 hasConcept C168563851 @default.
• W4246041230 hasConcept C1862650 @default.
• W4246041230 hasConcept C27415008 @default.
• W4246041230 hasConcept C2775930923 @default.
• W4246041230 hasConcept C2779363104 @default.
• W4246041230 hasConcept C2779951463 @default.
• W4246041230 hasConcept C2908647359 @default.
• W4246041230 hasConcept C530470458 @default.
• W4246041230 hasConcept C71924100 @default.
• W4246041230 hasConcept C99454951 @default.
• W4246041230 hasConceptScore W4246041230C121608353 @default.
• W4246041230 hasConceptScore W4246041230C126322002 @default.
• W4246041230 hasConceptScore W4246041230C133925201 @default.
• W4246041230 hasConceptScore W4246041230C159110408 @default.
• W4246041230 hasConceptScore W4246041230C168563851 @default.
• W4246041230 hasConceptScore W4246041230C1862650 @default.
• W4246041230 hasConceptScore W4246041230C27415008 @default.
• W4246041230 hasConceptScore W4246041230C2775930923 @default.
• W4246041230 hasConceptScore W4246041230C2779363104 @default.
• W4246041230 hasConceptScore W4246041230C2779951463 @default.
• W4246041230 hasConceptScore W4246041230C2908647359 @default.
• W4246041230 hasConceptScore W4246041230C530470458 @default.

• next